New hope for leukemia: immunotherapy combo aims to reduce transplants
NCT ID NCT06860269
First seen Feb 16, 2026 · Last updated May 24, 2026 · Updated 16 times
Summary
This study tests whether adding newer immunotherapy drugs to standard treatment can improve survival and reduce the need for stem cell transplants in adults with acute lymphoblastic leukemia (ALL). About 1,200 participants aged 18-65 with newly diagnosed ALL will be assigned to one of three groups based on their leukemia type. The goal is to see if these combinations can keep the cancer away longer and help more people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Saint Louis
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.